21 CFR 316.14 - Refusal to provide written recommendations.
(a) FDA may refuse to provide written recommendations concerning the nonclinical laboratory studies and clinical investigations necessary for approval of a marketing application for any of the following reasons:
(1) The information required to be submitted by § 316.10(b) has not been submitted, or the information submitted is incomplete.
(2) There is insufficient information about:
(i) The drug to identify the active moiety and its physical and chemical properties, if these characteristics can be determined; or
(ii) The disease or condition to determine that the disease or condition is rare in the United States; or
(iii) The reasons for believing that the drug may be useful for treating the rare disease or condition with that drug; or
(iv) The regulatory and marketing history of the drug to determine the scope and type of investigations that have already been conducted on the drug for the rare disease or condition; or
(v) The plan of study for establishing the safety and effectiveness of the drug for treatment of the rare disease or condition.
(3) The specific questions for which the sponsor seeks the advice of the agency are unclear or are not sufficiently specific.
(4) On the basis of the information submitted and on other information available to the agency, FDA determines that the disease or condition for which the drug is intended is not rare in the United States.
(5) On the basis of the information submitted and on other information available to the agency, FDA determines that there is an inadequate basis for permitting investigational use of the drug under part 312 of this chapter for the rare disease or condition.
(6) The request for information contains an untrue statement of material fact.
(b) A refusal to provide written recommendations will be in writing and will include a statement of the reason for FDA's refusal. Where practicable, FDA will describe the information or material it requires or the conditions the sponsor must meet for FDA to provide recommendations.
(1) Provide the information or material or amend the request for written recommendations to meet the conditions sought by FDA; or
(2) Withdraw the request for written recommendations. FDA will consider a sponsor's failure to respond within 90 days to an FDA letter requesting information or material or setting forth conditions to be met to be a withdrawal of the request for written recommendations.
Title 21 published on 09-Nov-2018 03:23
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR Part 316 after this date.